Monopar Therapeutics Inc. 8-K Report: Key Insights & Updates (Dec 20, 2024)

Based on the provided XML section of the financial report, here are the key pieces of information extracted:

Entity Information:

Company Name: Monopar Therapeutics Inc.
CIK (Central Index Key): 0001645469
IRS Employer Identification Number (EIN): 32-0463781
Address: 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091
Phone Number: 847-388-0349

Filing Details:

Filing Type: 8-K (Current Report)
Filing Date: December 20, 2024
SEC File Number: 001-39070

Stock Information:

Common Stock Par Value: $0.001
Ticker Symbol: MNPR
Exchange: NASDAQ

Report Date Context:

Report Period: December 20, 2024 (Note: The start and end dates are the same, indicating a specific event or information being reported on that day)

Insights:

The report is a current report (8-K), which is typically used to announce major events that shareholders should know about. The specific nature of the event isn't detailed in the provided section.
The company is publicly traded on NASDAQ under the ticker symbol MNPR, indicating it is subject to regulatory requirements and regular financial reporting.
The exact details regarding the content of the 8-K filing (such as the nature of the event) are not provided, but further context would be necessary to evaluate its significance in terms of financial performance or business developments.

This information is essential for shareholders, analysts, and other stakeholders to assess the company's current status and any significant changes or events that may impact its operations or financial performance.